Ziginskiene Edita, Kuzminskis Vytautas, Petruliene Kristina, Vaiciuniene Ruta, Stankuviene Asta, Bumblyte Inga Arune
Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Mickeviciaus str. 9, LT-44307 Kaunas, Lithuania ; Nephrological Clinic, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Eiveniu str. 2, LT-50009 Kaunas, Lithuania.
ScientificWorldJournal. 2013 Dec 3;2013:260915. doi: 10.1155/2013/260915. eCollection 2013.
Erythropoietin stimulating agents had a long haul in Lithuania--we had no epoetin till 1994 and there was no intravenous iron in 2001-2004. The aim of this study was to assess the changes of renal anemia control in hemodialysis patients from early independence of Lithuania till nowadays and to evaluate the link of anemia with hospitalization rates and survival and hemoglobin variability in association with mortality. In December of each year since 1996 all hemodialysis centers have been visited and data has been collected using special questionnaires. The history of renal anemia control in Lithuania was complicated; however, a significant improvement was achieved: 54.7% of hemodialysis patients reached the target hemoglobin; all patients have a possibility of treatment with epoetin and intravenous iron. The involuntary experiment with an intravenous iron occurred in Lithuania because of economic reasons and confirmed the significant role of intravenous iron in the management of renal anemia. Hemoglobin below 100 g/L was associated with a 2.5-fold increase in relative risk of death and 1.7-fold increase in relative risk of hospitalization in Lithuanian hemodialysis patients. Although hemoglobin variability was common in Lithuanian hemodialysis patients, we did not find the association between hemoglobin variability and all-cause mortality in our study.
促红细胞生成素刺激剂在立陶宛的应用历程漫长——1994年之前我们没有促红细胞生成素,2001年至2004年期间没有静脉铁剂。本研究的目的是评估从立陶宛早期独立至今血液透析患者肾性贫血控制情况的变化,并评估贫血与住院率、生存率以及血红蛋白变异性与死亡率之间的关联。自1996年起,每年12月都会走访所有血液透析中心,并使用专门的问卷收集数据。立陶宛肾性贫血的控制历程较为复杂;然而,已取得显著改善:54.7%的血液透析患者达到了血红蛋白目标值;所有患者都有可能接受促红细胞生成素和静脉铁剂治疗。由于经济原因,立陶宛出现了静脉铁剂的非自愿试验,证实了静脉铁剂在肾性贫血管理中的重要作用。在立陶宛血液透析患者中,血红蛋白低于100 g/L与死亡相对风险增加2.5倍以及住院相对风险增加1.7倍相关。尽管立陶宛血液透析患者中血红蛋白变异性很常见,但在我们的研究中未发现血红蛋白变异性与全因死亡率之间的关联。